Polyglucosamine L112

DEVICE3 trials

Sponsors

Certmedica International GmbH, Azienda di Servizi alla Persona di Pavia

Conditions

Cholesterol LoweringObesityWeight Loss

Phase 4

Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate Obese and Overweight Subjects

CompletedNCT04375696

Certmedica International GmbHWeight Loss

Start: 2020-04-24End: 2021-12-20Updated: 2022-11-22

Unknown Phase

Polyglucosamine L112 in Overweight and Obese Subjects

CompletedNCT05022732

Azienda di Servizi alla Persona di PaviaObesity

Start: 2020-05-05End: 2021-08-19Updated: 2021-08-26

Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption

CompletedNCT05038436

Certmedica International GmbHCholesterol Lowering

Start: 2021-09-16End: 2022-06-21Updated: 2022-11-18

Related Papers

Modification of metabolic syndrome parameters following the administration of polyglucosamine L112: results of a subgroup analysis of subjects enrolled in a double blind randomised placebo controlled clinical investigation.

2025-09-02